Tag:

Diagnostics

Health

syphilis screenings needed pregnancy STIs

by Chief Editor
written by Chief Editor

The Rising Tide of Congenital Syphilis: Why Prenatal Screening Lags and What’s Next

Despite legal mandates for comprehensive syphilis testing during pregnancy, a significant gap remains in ensuring expectant mothers receive the recommended screenings. New data presented at IDWeek 2025 reveals that fewer than one in five pregnant patients at a major North Carolina health system completed all three required tests. This shortfall is occurring amidst a national surge in congenital syphilis, raising critical questions about access to care and the effectiveness of current public health strategies.

Persistent Gaps in Screening: A Closer Look

Researchers at the University of North Carolina School of Medicine analyzed over 96,000 pregnancy episodes between 2019 and 2023. While 88.8% of pregnancies included at least one syphilis test, full compliance with the three-timepoint screening protocol – first prenatal visit, 28-30 weeks and delivery – was only 15.5%. The most significant drop-off occurred in the late second trimester, with only 24% of patients tested between 28 and 31 weeks.

These findings aren’t isolated. National data from the CDC shows a disturbing trend: nearly 4,000 cases of newborn syphilis were reported in 2024, marking the twelfth consecutive year of increase. This represents a nearly 700% rise since 2015, when just 495 cases were reported. While the rate of increase slowed slightly in 2024, the overall numbers remain alarmingly high.

Disparities in Access and Care

The UNC study similarly highlighted significant disparities in screening rates. Black women, patients insured through Medicaid, and those requiring language assistance were less likely to complete all three screening tests. This underscores the role of structural barriers in accessing consistent prenatal care and the need for targeted interventions to address inequities.

“This suggests a need for structural interventions to support access to care for all pregnant patients,” stated Dr. Stephanie Sweitzer, the presenting author of the UNC study.

The Call for Innovative Solutions

Experts are urging a shift towards more proactive and accessible screening methods. Jeffrey Klausner, MD, MPH, of USC Keck School of Medicine, emphasized the need for new strategies, including the implementation of rapid, point-of-care syphilis tests. These tests can deliver results in as little as 10 minutes, enabling immediate treatment and preventing transmission to the fetus.

Other proposed solutions include implementing standing orders in laboratory workflows to automatically include syphilis testing with routine prenatal blood panels, and increasing accountability from state and local health departments to ensure consistent screening practices.

Pro Tip: Healthcare providers should familiarize themselves with the latest syphilis screening guidelines and advocate for policies that streamline access to testing for all pregnant patients.

Future Trends and Potential Impacts

The congenital syphilis crisis is likely to continue unless significant changes are made to prenatal care practices. Several trends are expected to shape the future of this issue:

  • Increased Adoption of Point-of-Care Testing: Rapid tests will turn into more widely available, particularly in underserved communities.
  • Enhanced Data Tracking and Surveillance: Improved data collection and analysis will help identify areas with the greatest need and track the effectiveness of interventions.
  • Expanded Public Health Initiatives: Increased funding for public health programs focused on syphilis prevention and treatment will be crucial.
  • Telehealth Integration: Telehealth platforms can be used to provide remote counseling and support to pregnant patients, improving access to care.

FAQ: Congenital Syphilis and Prenatal Screening

Q: What is congenital syphilis?
A: Congenital syphilis is a serious infection passed from a mother to her baby during pregnancy. It can cause severe health problems, including stillbirth, premature birth, and lifelong disabilities.

Q: Why is prenatal syphilis screening important?
A: Early detection and treatment of syphilis during pregnancy can prevent congenital syphilis and protect the health of both mother and baby.

Q: What are the recommended syphilis screening times during pregnancy?
A: Screening is recommended at the first prenatal visit, again at 28-30 weeks, and at delivery.

Q: What can be done to improve syphilis screening rates?
A: Implementing rapid testing, streamlining laboratory workflows, and addressing social determinants of health are key strategies.

Did you realize? Syphilis is a curable infection. Early treatment with antibiotics can prevent congenital syphilis in almost all cases.

This ongoing crisis demands a multifaceted approach, combining improved screening practices, targeted interventions for vulnerable populations, and a renewed commitment to public health. The health of future generations depends on it.

What are your thoughts on this issue? Share your comments below and let’s continue the conversation.

0 comments
0 FacebookTwitterPinterestEmail
Health

Abbott completes acquisition of Exact Sciences

by Chief Editor
written by Chief Editor

Abbott’s Bold Move: Reshaping the Future of Cancer Diagnostics

Abbott has finalized its acquisition of Exact Sciences, a strategic move poised to redefine the landscape of cancer screening and diagnostics. The deal, completed on March 23, 2026, establishes Abbott as a major player in a rapidly expanding market, with the potential to impact millions of lives.

A $60 Billion Opportunity: The Rise of Preventative Oncology

The acquisition positions Abbott to capitalize on the growing $60 billion U.S. Cancer screening and precision oncology diagnostics segment. This surge is driven by an increasing global cancer incidence and a shift towards preventative healthcare. Rather than solely focusing on treatment, the emphasis is now on early detection and personalized interventions.

Expanding Access to Cutting-Edge Cancer Screening Technologies

Exact Sciences brings a suite of industry-leading products to Abbott, including Cologuard®, a noninvasive colorectal cancer screening test and Oncotype DX®, which guides personalized breast cancer treatment decisions. The addition of Oncodetect® and Cancerguard® further strengthens Abbott’s pipeline, offering tools for monitoring cancer recurrence and multi-cancer early detection.

Global Reach and Operational Excellence

According to Abbott CEO Robert B. Ford, the company’s global scale and operational expertise will be instrumental in expanding access to these vital tools. Abbott’s established infrastructure, particularly in Europe and Asia, will facilitate the launch of Cologuard and Oncotype DX in underserved regions, addressing disparities in cancer screening rates.

Beyond the U.S.: International Expansion is Key

Even as Exact Sciences achieved significant success within the U.S. Market, its international presence was limited. Abbott’s existing global network provides a crucial platform for extending the reach of Exact Sciences’ technologies, bringing the benefits of early cancer detection to a wider population.

The Power of Personalized Medicine

The integration of Exact Sciences’ pipeline aligns with the growing trend towards personalized medicine. By providing more preventative, predictive, and personalized diagnostics, Abbott aims to optimize treatment decisions and improve patient outcomes. This includes identifying individuals at higher risk, tailoring therapies to specific cancer subtypes, and monitoring treatment response.

What Does This Mean for Patients?

This acquisition translates to potentially earlier cancer detection, more informed treatment choices, and improved overall survival rates. The combination of Abbott’s resources and Exact Sciences’ innovative technologies promises to accelerate the development and deployment of next-generation cancer diagnostics.

Frequently Asked Questions

  • What does Abbott’s acquisition of Exact Sciences mean for shareholders? Exact Sciences shares ceased trading on the Nasdaq Stock Market on March 20, 2026, as it became a wholly-owned subsidiary of Abbott.
  • What types of cancer will these new diagnostics focus on? The initial focus includes colorectal and breast cancer, with a broader pipeline targeting multiple cancer types through early detection blood tests and monitoring tools.
  • Will this acquisition increase healthcare costs? While the initial investment is significant, the long-term goal is to reduce healthcare costs by enabling earlier detection and less invasive treatments.

Pro Tip: Early detection is often the key to successful cancer treatment. Talk to your doctor about appropriate screening options based on your age, family history, and risk factors.

Explore more about Abbott’s commitment to healthcare innovation at abbott.com.

0 comments
0 FacebookTwitterPinterestEmail
Tech

New terahertz imaging system enables faster clinical diagnostics

by Chief Editor
written by Chief Editor

Terahertz Imaging: A Recent Era of Real-Time, Non-Invasive Diagnostics

A groundbreaking development from the University of Warwick and University of Exeter is poised to revolutionize medical diagnostics. Scientists have created a fully fibre-coupled terahertz (THz) imaging system that dramatically improves the speed, resolution, and practicality of this promising technology. This innovation brings real-time, non-invasive tissue imaging significantly closer to becoming a standard practice in clinical settings.

The Limitations of Current Imaging Technologies

Traditional medical imaging techniques, like X-rays and CT scans, often involve ionizing radiation, raising concerns about long-term health risks. While MRI and ultrasound offer safer alternatives, they can be slow, expensive, or lack the resolution needed for certain applications. Existing terahertz imaging systems, despite their potential, have been hampered by bulkiness and slow acquisition speeds, restricting their use to specialized laboratories.

How Terahertz Imaging Works – and Why It’s a Game Changer

Terahertz waves, positioned on the electromagnetic spectrum between microwaves and infrared light, offer a unique set of properties. They are non-ionizing, eliminating the risks associated with X-rays, and highly sensitive to water content. This sensitivity is crucial as variations in water content often distinguish between healthy and diseased tissue. The new system developed by the Warwick team leverages these properties with unprecedented efficiency.

A Compact and Rapid System

The key breakthrough lies in the system’s fibre-coupling design. This streamlined approach delivers near video-rate imaging with a spatial resolution of approximately 360 µm – more than five times faster than current state-of-the-art systems. The compact and adaptable design allows for potential use as a handheld device or integration with robotic surgical tools. Professor Emma MacPherson, Department of Physics, University of Warwick, explains, “It’s an exciting breakthrough as the fibre coupling means that the system can be flexible and compact.”

Successful Demonstrations and Potential Applications

Proof-of-concept demonstrations have already yielded promising results. The system successfully differentiated between various biological tissues, including fat and protein in pig samples. It captured real-time images of a wound on a volunteer’s arm. This opens up possibilities for rapid, non-invasive diagnosis in a variety of clinical scenarios.

Potential applications extend beyond wound assessment. The technology could be used to assess suspicious skin lesions in real time, aiding in the early detection of skin cancers. It could also improve the precision of surgical removal of skin cancers, minimizing damage to healthy tissue.

The Future of Terahertz Imaging: Beyond the Lab

This advancement represents a significant step toward practical clinical terahertz imaging and real-time medical diagnostics. The ability to bring this technology beyond the laboratory and into everyday clinical use could lead to faster diagnoses, fewer invasive procedures, and more confident decision-making for clinicians. Professor MacPherson adds, “For patients, that could mean faster answers and fewer invasive procedures.”

Did you know? Terahertz waves can penetrate materials that are opaque to visible light, making them useful for security screening and industrial quality control as well as medical diagnostics.

FAQ

What are terahertz waves? Terahertz waves are a form of electromagnetic radiation between microwaves and infrared light.

Are terahertz waves harmful? No, terahertz waves are non-ionizing and do not carry the risks associated with X-rays.

What makes this new system different? This system is significantly faster, more compact, and more flexible than previous terahertz imaging systems.

What are the potential applications of this technology? Potential applications include wound assessment, skin cancer detection, and surgical guidance.

Pro Tip: The sensitivity of terahertz imaging to water content makes it particularly useful for detecting changes in tissue hydration, a common indicator of disease.

Learn more about the research published in Nature Communications.

What are your thoughts on the future of non-invasive medical imaging? Share your comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Siemens Healthineers launches brain health research portfolio with first biomarker assays now available

by Chief Editor
written by Chief Editor

The Dawn of Blood-Based Brain Health: How New Assays are Changing Alzheimer’s Research

The landscape of brain health research is undergoing a significant shift, moving towards less invasive diagnostic tools. Siemens Healthineers has recently expanded its portfolio with new blood-based assays for phosphorylated tau 217 (pTau217) and Brain Derived Tau (BDTau), offering researchers a powerful new way to study neurodegenerative diseases like Alzheimer’s. This development arrives at a critical time, with nearly 10 million new dementia cases diagnosed globally each year, and Alzheimer’s accounting for 60-70% of those.

From Spinal Taps to Simple Blood Draws: A Less Invasive Future

Traditionally, diagnosing and researching Alzheimer’s disease relied heavily on cerebrospinal fluid (CSF) analysis, requiring a lumbar puncture – a procedure often perceived as uncomfortable and carrying some risk. These new blood-based biomarker tests offer a compelling alternative. They provide a quantitative measurement of p-tau217 and BD Tau using chemiluminescent immunoassays, and are compatible with widely used Atellica Solution IM and Atellica CI Analyzers. This accessibility promises to accelerate research and potentially broaden access to diagnostic testing.

“Siemens Healthineers is laser focused on expanding researchers’ access to blood testing that can reduce the burden of invasive testing to better understand these diseases and help address the growing societal impact of neurodegenerative conditions,” says Jim Freeman, Head of Core Laboratory Solutions R&D for Diagnostics at Siemens Healthineers. The sensitivity of the Atellica IM instrument is key to detecting these neurological biomarkers in blood.

The Power of Blood Biomarkers: Scaling Research and Patient Care

The advantages of blood-based testing extend beyond patient comfort. As neuroscientist Henrik Zetterberg, MD, PhD, explains, “Blood tests are much easier for both patients and doctors – you can scale testing, follow patients, or perhaps prepare a biomarker portfolio.” This scalability is crucial for large-scale research studies and, eventually, for widespread clinical application.

Collaborative Research Driving Innovation

Siemens Healthineers isn’t working in isolation. The company is actively involved in research collaborations with organizations like PREDICTOM, ACCESS-AD, and Banner Sun Health Research Institute. These partnerships are focused on validating the clinical utility of p-tau217 as a biomarker for early Alzheimer’s detection across diverse patient populations.

Nicholas Ashton, PhD, senior director of the Fluid Biomarker Program at Banner Sun Health Research Institute, highlights the value of these collaborations: “We value the opportunity to work with the leading diagnostics companies to advance the fight against Alzheimer’s disease, and this is a great example.” Their findings suggest the promise of this Alzheimer’s blood biomarker in a clinical setting.

Beyond Alzheimer’s: Expanding the Horizon of Brain Health Diagnostics

The focus isn’t solely on Alzheimer’s. Siemens Healthineers already offers an assay with CE mark to predict the risk of future Multiple Sclerosis disease activity. Development is underway for additional biomarkers, including Apolipoprotein E-ε4 (ApoE-ε4), a protein linked to both Alzheimer’s disease and cardiovascular diseases. This broader approach signals a commitment to comprehensive brain health diagnostics.

Future Trends: What’s Next for Blood-Based Brain Health?

Personalized Medicine and Early Intervention

The advent of reliable blood biomarkers paves the way for personalized medicine in neurodegenerative diseases. Identifying individuals at risk *before* symptoms manifest will allow for earlier interventions, potentially slowing disease progression or even preventing onset.

Multi-Biomarker Panels for Enhanced Accuracy

Future diagnostic tests are likely to incorporate panels of multiple biomarkers, rather than relying on a single marker. Combining p-tau217, BD Tau, ApoE-ε4, and other relevant biomarkers will provide a more comprehensive and accurate assessment of an individual’s risk and disease stage.

Integration with Digital Health Technologies

Expect to see integration of blood biomarker data with digital health technologies, such as wearable sensors and mobile apps. This will enable continuous monitoring of brain health indicators and facilitate remote patient management.

FAQ

Q: What is a biomarker?
A: A biomarker is a measurable indicator of a biological state or condition. In the context of Alzheimer’s disease, biomarkers can help identify changes in the brain associated with the disease process.

Q: How do the Siemens Healthineers assays work?
A: The assays use chemiluminescent immunoassays to quantitatively measure levels of p-tau217 and BD Tau in blood samples.

Q: Are these tests available to the general public?
A: Currently, these assays are primarily intended for research use. Widespread clinical availability will depend on further validation and regulatory approvals.

Q: What is the significance of p-tau217?
A: p-tau217 is a specific form of tau protein that is strongly associated with Alzheimer’s disease pathology and is considered a promising biomarker for early detection.

Did you know? Alzheimer’s disease affects millions worldwide, and early detection is crucial for improving patient outcomes.

Pro Tip: Stay informed about the latest advancements in brain health research by following reputable organizations like the Alzheimer’s Association and the National Institute on Aging.

Interested in learning more about the latest breakthroughs in neurological diagnostics? Explore our other articles or subscribe to our newsletter for regular updates.

0 comments
0 FacebookTwitterPinterestEmail
Tech

Defining the limits of immunotherapy in early small-cell lung cancer

by Chief Editor
written by Chief Editor

Immunotherapy Plateau? New Data Shifts Focus Back to Radiation in Small Cell Lung Cancer

A recent international clinical trial, NRG-LU005, has delivered a nuanced message in the fight against limited-stage small cell lung cancer (LS-SCLC). While the addition of immunotherapy drug atezolizumab to standard chemoradiation didn’t significantly improve overall survival, a surprising trend emerged: twice-daily radiation therapy demonstrated a consistent survival benefit. The findings, published in the Journal of Clinical Oncology, are prompting a re-evaluation of treatment strategies for this aggressive cancer.

The Immunotherapy Promise and the LU005 Results

Immunotherapy has revolutionized cancer treatment, showing remarkable success in many advanced cancers, including extensive-stage SCLC. Researchers hoped extending its leverage to earlier, potentially curable stages like LS-SCLC would yield similar benefits. Though, NRG-LU005, involving 544 patients across the US and Japan between May 2019 and December 2023, showed that adding atezolizumab to chemoradiation didn’t translate into improved overall or progression-free survival.

The median overall survival was 36.1 months for those receiving chemoradiation alone, compared to 31.1 months for those also receiving atezolizumab. Progression-free survival was 11.4 months and 12.1 months, respectively. Importantly, the study did not reveal any new or unexpected safety concerns with the addition of atezolizumab.

Twice-Daily Radiation: A Resurgence of an Old Strategy

Despite the immunotherapy results, the trial highlighted the significant impact of radiation fractionation – how radiation is delivered. Patients receiving radiation twice daily experienced substantially better survival rates than those receiving it once daily, regardless of whether they also received atezolizumab.

In the chemoradiation-alone arm, patients on once-daily radiation had a 51% higher risk of death compared to those treated twice daily. This finding reinforces evidence from trials dating back to the 1990s, yet adoption of twice-daily radiation remains surprisingly low, often due to logistical challenges for patients and healthcare providers.

Why Twice-Daily Radiation Works

The benefit of twice-daily radiation likely stems from its ability to deliver a higher total dose of radiation while minimizing damage to surrounding healthy tissues. The fractionation schedule allows for more frequent, smaller doses, which are more effective at killing cancer cells.

“By combining contemporary trial methodology, a robust sample size and stringent quality assurance requirements, LU005 provides one of the strongest modern validations that 45 Gy delivered twice daily should remain the preferred thoracic radiation schedule for patients with limited-stage SCLC,” explained Dr. Helen J. Ross, co-principal investigator of LU005.

Implications for Future Treatment Approaches

The NRG-LU005 trial doesn’t signal the end of immunotherapy research in LS-SCLC, but it does suggest a need to refine strategies. Future research may focus on identifying biomarkers to predict which patients are most likely to benefit from immunotherapy, or exploring different combinations and sequencing of treatments.

The renewed emphasis on radiation fractionation also opens avenues for investigation. Researchers could explore ways to overcome the logistical hurdles associated with twice-daily radiation to improve access for more patients.

FAQ

Q: Does this mean immunotherapy is ineffective for limited-stage SCLC?
A: Not necessarily. It suggests that adding atezolizumab to standard chemoradiation doesn’t provide a significant benefit in this setting, but further research is needed to explore other immunotherapy approaches.

Q: What is radiation fractionation?
A: Radiation fractionation refers to how radiation therapy is delivered – the number of doses and the size of each dose.

Q: Why isn’t twice-daily radiation more common if it’s more effective?
A: Twice-daily radiation can be logistically challenging for patients and healthcare providers, requiring more frequent hospital visits.

Q: What were the key endpoints of the NRG-LU005 trial?
A: The primary endpoint was overall survival. Secondary endpoints included progression-free survival, distant metastasis-free survival, objective response rate, local control, and safety.

Did you know? The 36.1-month median overall survival in the standard chemoradiation arm represents one of the longest survival outcomes ever reported in a randomized study in people with limited-stage SCLC.

Pro Tip: If you or a loved one is diagnosed with limited-stage SCLC, discuss all treatment options, including radiation fractionation schedules, with your oncologist.

Stay informed about the latest advancements in cancer treatment. Explore more research from NRG Oncology and learn about clinical trials from the Alliance for Clinical Trials in Oncology.

0 comments
0 FacebookTwitterPinterestEmail
Health

Biomimetic smart insole system enables accurate gait monitoring

by Chief Editor
written by Chief Editor

The Future of Footwear: Smart Insoles and the Rise of Predictive Gait Analysis

As populations age and chronic conditions develop into more prevalent, maintaining mobility is paramount. A new generation of smart insoles, inspired by the intricate mechanics of the mantis leg, is poised to revolutionize how we monitor, diagnose, and treat lower limb dysfunction. These aren’t just comfort enhancements; they’re sophisticated diagnostic tools stepping into the realm of preventative healthcare.

Beyond Step Counters: The Evolution of Gait Analysis

Traditional gait analysis, crucial for evaluating lower limb function and rehabilitation progress, has historically been confined to laboratory settings. Optical motion capture systems and force platforms, while accurate, are expensive, cumbersome, and fail to capture natural movement patterns. Wearable pressure-sensing insoles offer a compelling alternative – continuous, decentralized monitoring in real-world environments. However, previous iterations faced limitations in sensor sensitivity, power supply, and data analysis.

Biomimicry in Action: The Mantis Leg Inspiration

Recent research has overcome these hurdles by drawing inspiration from nature. A novel biomimetic smart insole system, detailed in Research, mimics the hierarchical mechanosensory structure of the mantis leg. This design incorporates a dual-microstructure capacitive pressure sensor, combining microstructured PDMS with compressible elastic foam. The result? An ultra-low detection limit of 0.10 Pa, a wide detection range up to 1.4 MPa, and exceptional mechanical stability – significantly exceeding the performance of existing flexible pressure sensors.

Powering the Future: Sustainable Energy for Wearable Tech

A major challenge for wearable devices is consistent power. This new system tackles this with an integrated perovskite solar cell and a high-energy-density lithium-sulfur nanobattery. This closed-loop, adaptive energy supply system operates reliably under various lighting conditions, boasting an average light charging efficiency of 11.21% and an energy storage efficiency of 72.15%. This addresses the critical need for continuous, long-term monitoring without frequent charging.

AI-Powered Diagnostics: From Data to Insights

The smart insole doesn’t just collect data; it interprets it. A 16-channel wireless module transmits plantar spatiotemporal pressure distribution to embedded artificial intelligence algorithms for real-time analysis. Utilizing a random forest model, the system achieves 96.0% accuracy in identifying arch abnormalities. A one-dimensional convolutional neural network (1D-CNN) classifies 12 pathological gait patterns with an impressive 97.6% accuracy. This data is then presented to clinicians and rehabilitation personnel through an intuitive mobile app, featuring color maps that visualize dynamic force field distribution.

Expanding Applications: Beyond Clinical Settings

The potential applications extend far beyond traditional clinical settings. Consider these emerging trends:

  • Personalized Rehabilitation: Tailoring rehabilitation programs based on real-time gait analysis, optimizing recovery and preventing re-injury.
  • Remote Patient Monitoring: Enabling healthcare providers to remotely monitor patients’ gait patterns, identifying potential issues before they escalate.
  • Early Disease Screening: Identifying subtle gait changes that may indicate the onset of neurological disorders or musculoskeletal conditions.
  • Athletic Performance Enhancement: Analyzing gait mechanics to optimize athletic technique and reduce the risk of injury.
  • Fall Prevention: Identifying individuals at risk of falls based on gait instability, particularly relevant for older adults.

The Rise of Predictive Gait Analysis

The integration of AI and machine learning is driving the evolution towards predictive gait analysis. By analyzing longitudinal data, these systems can potentially forecast future mobility issues and proactively intervene. This shift from reactive to preventative care represents a significant advancement in healthcare.

Did you know? Subtle changes in gait can be early indicators of conditions like Parkinson’s disease, even before other symptoms manifest.

FAQ

Q: How accurate are these smart insoles?
A: The reported accuracy for arch abnormality identification is 96.0%, and for pathological gait pattern classification, it’s 97.6%.

Q: How long do the insoles need to be worn to collect meaningful data?
A: Data collection duration depends on the specific application, but continuous monitoring over several days or weeks can provide a comprehensive gait profile.

Q: Are these insoles available to consumers yet?
A: While still largely in the research and development phase, commercially available smart insoles with similar functionalities are beginning to emerge.

Pro Tip: When considering smart insoles, appear for features like wireless connectivity, long battery life, and compatibility with your smartphone or other devices.

The development of biomimetic smart insoles represents a significant step towards a future where footwear isn’t just about comfort and style, but about proactive health management. As the technology matures and becomes more accessible, You can expect to see a widespread adoption of these innovative tools, transforming the way we understand and care for our lower limbs.

Want to learn more about wearable health technology? Explore our other articles on remote patient monitoring and the future of preventative healthcare.

0 comments
0 FacebookTwitterPinterestEmail
Health

MiraDx launches new PROSTOX genetic test for prostate cancer patients

by Chief Editor
written by Chief Editor

Personalized Prostate Cancer Treatment: A New Era of Genetic Testing

MiraDx has recently launched PROSTOX Standard, a new genetic test designed to personalize radiation therapy for men with localized prostate cancer. This launch expands access to genetic-based risk assessment, complementing their existing PROSTOX Ultra test for patients considering stereotactic body radiation therapy (SBRT). The core benefit? Identifying those at higher risk of long-term urinary side effects from radiation treatment.

The Challenge of Radiation Toxicity

External beam radiation therapy (EBRT) remains a cornerstone of prostate cancer treatment, boasting a high five-year survival rate – over 99% for localized cases. Yet, over 20% of patients experience persistent urinary side effects, known as late genitourinary (GU) toxicity. These side effects, including urgency, leakage, and discomfort, can significantly diminish quality of life, appearing months or even years after treatment completion.

How PROSTOX Works: A Genetic Deep Dive

PROSTOX tests analyze inherited genetic variants in microRNAs and their associated pathways. These genetic factors influence how individual patients respond to radiation. A simple cheek swab provides the sample, with results available in 5-7 days. This allows physicians and patients to collaborate on more informed treatment decisions, tailored to each patient’s unique risk profile.

“PROSTOX tests bring precision medicine to radiation oncology,” explains Melissa C. Stoppler, MD, Executive Vice President of Medical Affairs at MiraDx. “By shifting the focus to individual biology and treatment risks, we can help clinicians better tailor radiation treatments and avoid long-term side effects.”

PROSTOX Standard vs. PROSTOX Ultra: Understanding the Difference

It’s crucial to understand that PROSTOX Standard and PROSTOX Ultra assess risk across different radiation therapy regimens. A high-risk result on one test doesn’t necessarily translate to a high-risk result on the other. In a slight percentage of cases (less than 2%), both tests may indicate a high risk of late GU side effects, prompting consideration of alternative interventions.

The Future of Personalized Radiation Oncology

The introduction of PROSTOX Standard isn’t an isolated event; it’s a sign of a broader trend toward personalized radiation oncology. Several factors are driving this shift:

MicroRNA-Based Assays Gain Traction

Research suggests microRNA-based assays, like the one used in PROSTOX, can not only predict toxicity but too potentially reduce healthcare costs and improve quality-adjusted life years (QALYs) for prostate cancer patients. Economic evaluations are increasingly demonstrating the value of these tests.

Expanding Genetic Testing in Cancer Care

Genetic testing is becoming increasingly integrated into cancer care across multiple tumor types. As our understanding of the genetic basis of treatment response and toxicity grows, we can expect to see more tests like PROSTOX emerge, offering increasingly precise risk assessments.

The Rise of Multi-Omics Approaches

While PROSTOX focuses on microRNAs, the future likely holds multi-omics approaches. This involves integrating data from genomics, proteomics, metabolomics, and other “omics” fields to create a comprehensive picture of a patient’s individual risk profile. This holistic view will enable even more tailored treatment strategies.

AI and Machine Learning in Predictive Modeling

Artificial intelligence (AI) and machine learning (ML) are poised to play a significant role in analyzing the vast amounts of data generated by genetic testing and other sources. AI/ML algorithms can identify complex patterns and predict treatment outcomes with greater accuracy than traditional methods.

Patient Perspective: A Boost in Confidence

For patients like Ron Stewart, PROSTOX testing provides peace of mind. “Being diagnosed with prostate cancer is life altering,” Stewart shared. “The PROSTOX test helped me feel more confident about my treatment plan and more optimistic that my cancer treatment would not hamper my quality of life down the road.”

Did you know?

Late GU toxicity can significantly impact a patient’s daily life, affecting everything from physical activity to social interactions. Early identification of risk can allow for proactive management strategies.

Frequently Asked Questions (FAQ)

Q: What is genitourinary (GU) toxicity?
A: GU toxicity refers to side effects affecting the urinary and reproductive systems, such as urinary urgency, leakage, or discomfort, that can occur after radiation therapy for prostate cancer.

Q: How does PROSTOX testing differ from traditional risk assessment?
A: Traditional risk assessment relies on clinical factors. PROSTOX uses genetic information to provide a more personalized and biology-driven assessment of risk.

Q: Is PROSTOX testing covered by insurance?
A: Insurance coverage varies. Patients should check with their insurance provider for specific details.

Q: What if PROSTOX identifies a high risk for both SBRT and conventional radiation?
A: In these cases, other interventions may be considered to minimize the risk of side effects.

Q: How long does it take to get PROSTOX results?
A: Results are typically available within 5-7 days of receiving the cheek swab sample.

Pro Tip: Discuss the potential benefits and limitations of genetic testing with your oncologist to determine if it’s right for you.

Want to learn more about personalized cancer treatment options? Visit the MiraDx website to explore their range of genetic tests and resources.

0 comments
0 FacebookTwitterPinterestEmail
Business

Key study of Grail’s cancer detection test fails in setback for company

by Chief Editor
written by Chief Editor

Cancer Blood Test Setback: What the Grail Study Means for Early Detection

A recent study involving Grail’s Galleri blood test, designed for early cancer detection, has revealed the test did not meet its primary goal within England’s National Health Service (NHS) trial. This news sent Grail’s shares down 47% in after-hours trading, raising questions about the future of multi-cancer early detection (MCED) tests.

The Promise of Liquid Biopsies

Grail’s Galleri test, priced at $1,000, analyzes blood samples for signs of cancer DNA. The core idea behind liquid biopsies – detecting cancer from a blood sample – is revolutionary. Currently, many cancers are diagnosed at later stages, when treatment is more challenging. Early detection significantly improves patient outcomes.

How Galleri Works

The Galleri test aims to identify multiple cancer types through a single blood draw. It looks for methylation patterns, chemical modifications to DNA that can indicate the presence of cancer cells. Although the test has been commercially available, generating $136.8 million in revenue from 185,000 tests sold in 2025, it hasn’t yet received FDA approval.

What Went Wrong in the NHS Trial?

Details of the NHS trial’s shortcomings are limited due to the STAT+ exclusive nature of the full report. However, the failure to meet its primary goal suggests challenges in real-world application. Factors could include the test’s sensitivity – its ability to correctly identify cancer when it’s present – or its specificity – its ability to avoid false positives.

The Future of MCED Tests: A Bumpy Road Ahead?

Despite this setback, the field of MCED tests isn’t necessarily doomed. Grail plans to submit updated Galleri test data for FDA approval next year. This indicates the company remains committed to the technology. The path forward, however, will likely involve:

  • Improved Accuracy: Refining the test to reduce false positives and increase sensitivity is crucial.
  • Targeted Populations: Focusing on high-risk individuals might improve the test’s effectiveness.
  • Combination with Existing Screening: Integrating MCED tests with current cancer screening methods (like mammograms and colonoscopies) could offer a more comprehensive approach.

Samsung’s Investment and the Broader Biotech Landscape

Samsung’s recent $110 million investment in Grail highlights the continued interest in this technology. The biotech sector is actively exploring innovative diagnostic tools, and MCED tests represent a significant potential advancement.

Beyond Cancer: The ‘Holy Grail’ of Preventative Medicine

The pursuit of early disease detection extends beyond cancer. Research into a universal pandemic vaccine, described as the “holy grail” of pandemic preparedness, is ongoing. Similarly, advancements in weight loss treatments are showing promising results, potentially offering new solutions for obesity and related health issues.

FAQ

What is a liquid biopsy?
A liquid biopsy is a test that analyzes samples like blood to look for cancer cells or DNA from tumors.

Is the Galleri test available in the US?
Yes, but it is not yet approved by the Food and Drug Administration.

What are false positives?
A false positive means the test indicates cancer is present when it is not.

What is methylation?
Methylation is a chemical modification to DNA that can be an indicator of cancer.

What does this setback mean for cancer screening?
It highlights the challenges of developing effective early detection tests and the need for continued research and refinement.

Did you grasp? The concept of using blood tests to detect cancer dates back decades, but recent advances in genomics and biotechnology have made multi-cancer early detection a realistic possibility.

Pro Tip: Stay informed about the latest advancements in cancer screening and discuss your individual risk factors with your healthcare provider.

Want to learn more about the latest breakthroughs in cancer diagnostics? Subscribe to STAT+ for in-depth coverage and analysis.

0 comments
0 FacebookTwitterPinterestEmail
Health

Grail Cancer Blood Test Fails Key NHS Trial, Shares Plummet

by Chief Editor
written by Chief Editor

Cancer Blood Test Setback: What It Means for the Future of Early Detection

A recent study has cast a shadow over the promise of early cancer detection through blood tests. Grail’s Galleri test, a leading contender in this emerging field, failed to meet its primary goal in a large-scale trial with the UK’s National Health Service. This development raises critical questions about the viability of multi-cancer early detection (MCED) tests and their potential impact on healthcare.

The Promise and Peril of Liquid Biopsies

The concept behind liquid biopsies – detecting cancer signals in the blood – is revolutionary. Currently, many cancers are diagnosed at later stages, when treatment options are limited and outcomes are poorer. A successful blood test could identify cancers earlier, potentially leading to more effective interventions and improved survival rates. Grail’s Galleri test, priced at $1,000, already saw 185,000 tests sold in 2025, generating $136.8 million in revenue, demonstrating significant market interest despite lacking FDA approval.

Why Did the Grail Trial Fall Short?

Details surrounding the specific reasons for the trial’s failure are limited due to the STAT+ exclusive nature of the full report. However, the fact that the test didn’t achieve its main objective is a significant setback. It highlights the immense technical challenges involved in accurately detecting cancer signals amidst the complex background of a normal blood sample. False positives and false negatives remain major concerns.

The Impact on Investors and the Market

The news sent shockwaves through the financial markets, with Grail’s shares plummeting 47% in after-hours trading. This illustrates the high stakes and investor expectations surrounding MCED technology. While this setback is substantial, it doesn’t necessarily signal the end of the road for liquid biopsies. It does, however, underscore the need for more rigorous research, and development.

Beyond Grail: Other Players in the MCED Space

Grail isn’t the only company pursuing MCED tests. Several other firms are developing similar technologies, each with its own approach to cancer detection. The failure of the Galleri trial will likely prompt a reassessment of strategies and a renewed focus on improving test accuracy and clinical validation.

The Role of AI in Cancer Detection

Artificial intelligence is playing an increasingly important role in cancer diagnostics. AI-powered tools are being developed to analyze medical images, genomic data, and other sources of information to identify cancer patterns and predict treatment responses. As reported by Angus Chen of STAT, AI-powered cancer tools are beginning to hit the market, suggesting a growing integration of these technologies into clinical practice.

Looking Ahead: What’s Next for Early Cancer Detection?

Despite the recent setback, the pursuit of early cancer detection remains a critical area of research. Future trends are likely to include:

  • Improved Test Accuracy: Focus on refining existing technologies and developing new biomarkers to minimize false positives and false negatives.
  • Personalized Approaches: Tailoring tests to individual risk factors and genetic predispositions.
  • Combination Strategies: Integrating liquid biopsies with traditional screening methods, such as mammography and colonoscopy.
  • Focus on Specific Cancers: Developing tests targeted at cancers with limited early detection options.

FAQ

  • What is a liquid biopsy? A liquid biopsy is a test that analyzes samples of blood or other bodily fluids to look for cancer cells or DNA from cancer cells.
  • Is the Galleri test available in the US? No, the Galleri test is not yet approved by the Food and Drug Administration.
  • What caused Grail’s stock to drop? Grail’s stock dropped 47% after its cancer blood test failed to meet its main goal in a large study.
  • Who is Angus Chen? Angus Chen is a cancer reporter for STAT news, covering drugs, policy, science, and equity related to cancer.

Pro Tip: Stay informed about the latest advancements in cancer detection by following reputable sources like STAT News and consulting with your healthcare provider about appropriate screening options.

Want to learn more about the intersection of AI and cancer research? Explore more articles on STAT News.

0 comments
0 FacebookTwitterPinterestEmail
Tech

Engineered enzyme enables fast and accurate RNA synthesis

by Chief Editor
written by Chief Editor

The RNA Revolution: How a Latest Enzyme is Poised to Transform Medicine

RNA molecules are rapidly becoming the cornerstone of modern medicine, powering advancements in vaccines, diagnostics, and gene therapies. However, a significant bottleneck has hindered progress: the challenge of producing RNA quickly, accurately, and with the necessary flexibility for cutting-edge biomedical applications. Now, scientists at the University of California, Irvine (UCI) have unveiled a breakthrough that promises to overcome this hurdle.

Engineering Evolution: The Birth of Enzyme C28

A research team led by John Chaput, a professor of pharmaceutical sciences at UCI, has engineered a powerful new enzyme, dubbed C28, capable of efficiently synthesizing RNA. This achievement, detailed in a recent Nature Chemical Biology study, is particularly remarkable because naturally occurring DNA-copying enzymes cannot perform this function. C28 produces RNA at speeds comparable to natural processes while maintaining high fidelity and the ability to create long sequences.

The team didn’t rely on traditional enzyme redesign. Instead, they employed a technique called directed evolution. This involved creating millions of enzyme variants and testing them using a high-throughput screening platform, allowing evolution to “find unexpected structural solutions” to the problem of RNA synthesis. As Professor Chaput explained, “What surprised us is that we were able to overcome this barrier…by letting evolution find unexpected structural solutions.”

Beyond Speed and Accuracy: The Flexibility Factor

The significance of C28 extends beyond its speed and accuracy. Its ability to copy long sequences and handle customized or chemically modified RNA molecules opens up new possibilities for researchers and biotechnology developers. What we have is crucial for creating RNA-based therapies tailored to individual patients or designed to target specific diseases.

Pro Tip: The ability to modify RNA chemically is key to improving its stability and delivery within the body, addressing a major challenge in RNA-based drug development.

The Expanding Role of RNA in Healthcare

The development of C28 arrives at a pivotal moment. RNA technology has already demonstrated its potential with the rapid development of mRNA vaccines for COVID-19. This success has spurred increased investment and research into other RNA-based applications, including:

  • Cancer Immunotherapy: RNA vaccines can be designed to train the immune system to recognize and attack cancer cells.
  • Gene Editing: RNA molecules, like CRISPR guide RNAs, are essential components of gene editing technologies.
  • Diagnostics: RNA-based diagnostic tests can detect diseases earlier and more accurately.

The Power of Directed Evolution

The UCI team’s success highlights the immense potential of directed evolution as a tool for creating novel molecular functions. This approach allows scientists to bypass the limitations of naturally occurring enzymes and engineer solutions that were previously unimaginable. “This work shows that enzymes are far more adaptable than we once thought,” Chaput noted. “By harnessing evolution, we can create new molecular tools that open the door to advances in RNA biology, synthetic biology and biomedical innovation.”

FAQ: RNA Synthesis and the C28 Enzyme

Q: What is RNA synthesis?
A: RNA synthesis is the process of creating RNA molecules from a DNA template. It’s a fundamental process in biology and is crucial for gene expression.

Q: Why is efficient RNA synthesis important?
A: Efficient RNA synthesis is essential for developing new RNA-based therapies, diagnostics, and research tools.

Q: What makes the C28 enzyme unique?
A: C28 is an engineered enzyme that can efficiently synthesize RNA, a feat that natural DNA-copying enzymes cannot achieve.

Q: What is directed evolution?
A: Directed evolution is a technique that mimics natural selection in the lab to create enzymes with desired properties.

Did you know? The National Science Foundation provided funding for this groundbreaking research, demonstrating the importance of public investment in scientific innovation.

Explore more about the fascinating world of RNA and its potential to revolutionize healthcare. Share your thoughts in the comments below, and subscribe to our newsletter for the latest updates on biomedical breakthroughs.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts